

Amendments to the Claims:

Please cancel claims 1, 6, 8, 26, 28, 32, 48, 53, 55, 73, 75, 79 and 95 and add new claims 103-140. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-102. (Canceled)

103. (New) A fragment of A β consisting of the amino acid sequence KLVFFAED (residues 16-23 of SEQ ID NO:1).

104. (New) The fragment of claim 103, wherein the fragment is linked to a carrier molecule to form a conjugate which helps elicit an immune response against the fragment.

105. (New) The fragment of claim 104, wherein multiple copies of the fragment are linked to a single copy of the carrier.

106. (New) The fragment of claim 104, wherein a single copy of the fragment are linked to multiple copies of the carrier.

107. (New) The fragment of claim 104, wherein the fragment is linked to the carrier through a spacer.

108. (New) The fragment of claim 104, wherein the fragment is linked to the carrier by chemical crosslinking.

109. (New) The fragment of claim 104, wherein the carrier is a heterologous polypeptide.

110. (New) The fragment of claim 109, wherein the heterologous polypeptide comprises QYIKANSKFIGITEL (SEQ ID NO:8).

111. (New) The fragment of claim 109, wherein the heterologous polypeptide comprises the amino acid sequence AKXVAAWTLKAAA (SEQ ID NO:11).

112. (New) The fragment of claim 104, wherein the carrier is a diphtheria toxoid.

113. (New) The fragment of claim 103, further comprising a pharmaceutically acceptable vehicle.

114. (New) The fragment of claim 103, wherein the fragment is administered in a regime with an N-terminal A β fragment.

115. (New) The fragment of claim 114, wherein the N-terminal A β fragment is A β 1-5.

116. (New) The fragment of claim 114, wherein the N-terminal A β fragment is A β 1-6.

117. (New) The fragment of claim 114, wherein the N-terminal A β fragment is A β 1-7.

118. (New) A pharmaceutical composition comprising a fragment of A β consisting of the amino acid sequence KLVFFAED (residues 16-23 of SEQ ID NO:1) and a pharmaceutically acceptable vehicle.

119. (New) The composition of claim 118, wherein the fragment is linked to a carrier molecule to form a conjugate which helps elicit an immune response against the fragment.

120. (New) The composition of claim 119, wherein multiple copies of the fragment are linked to a single copy of the carrier.

121. (New) The composition of claim 119, wherein a single copy of the fragment are linked to multiple copies of the carrier.

122. (New) The composition of claim 119, wherein the fragment is linked to the carrier through a spacer.

123. (New) The composition of claim 119, wherein the fragment is linked to the carrier by chemical crosslinking.

124. (New) The composition of claim 118, wherein the carrier is a heterologous polypeptide.

125. (New) The composition of claim 124, wherein the heterologous polypeptide comprises QYIKANSKFIGITEL (SEQ ID NO:8).

126. (New) The composition of claim 124, wherein the heterologous polypeptide comprises the amino acid sequence AKXVAAWTLKAAA (SEQ ID NO:11).

127. (New) The composition of claim 119, wherein the carrier is a diphtheria toxoid.

128. (New) The composition of claim 118, further comprising an N-terminal A β fragment.

129. (New) The composition of claim 128, wherein the N-terminal fragment is A β 1-5.

130. (New) The composition of claim 128, wherein the N-terminal fragment is A β 1-6.

131. (New) The composition of claim 128, wherein the N-terminal fragment is A β 1-7.

132. (New) The composition of claim 118, further comprising an adjuvant.

133. (New) The composition of claim 132, wherein the adjuvant is alum.

134. (New) The composition of claim 132, wherein the adjuvant is MPL.

135. (New) The composition of claim 132, wherein the adjuvant is QS-21.

136. (New) The composition of claim 132, wherein the adjuvant is RC-529.

137. (New) The composition of claim 118, further comprising a surfactant.

138. (New) A vial comprising a pharmaceutical composition comprising a fragment of A β consisting of the amino acid sequence KLVFFAED (residues 16-23 of SEQ ID NO:1) in a pharmaceutically acceptable vehicle, and an adjuvant.

139. (New - Withdrawn) A method of prophylaxis of a disease associated with amyloid deposits of A β in the brain of a patient susceptible to the disease, comprising administering to the patient an effective regime of a fragment of A β consisting of the amino acid sequence KLVFFAED (residues 16-23 of SEQ ID NO:1), and thereby effect prophylaxis of the disease.

140. (New - Withdrawn) A method of treating a disease associated with amyloid deposits of A β in the brain of a patient susceptible to the disease, comprising administering to the patient an effective regime of a fragment of A β consisting of the amino acid sequence KLVFFAED (residues 16-23 of SEQ ID NO:1), and thereby treat the disease.